Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of cancer. The BeVigilant™ OraFusion System aids clinicians with identifying patients at risk for oral cancers. It is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant™ OraFusion System, the first and only technology that measures tumor-initiating and stem cell associated biomarkers – markers clinically validated to be associated with oral cancer – was developed to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant™ OraFusion System uses a simple collection method that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant™ OraFusion System is CE Marked and available in select markets outside of the United States. The BeVigilant™ OraFusion System is not available for sale in the U.S. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer